Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells

Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells

Objective Although anti-malarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ) are currently used for the treatment of systemic lupus erythematosus, their efficacy for lupus nephritis (LN) remains unclear. Given that upregulation of glomerular Toll-like receptor 3 (TLR3) signaling plays a pi...

Full description

Bibliographic Details
Main Authors:	Riko Sato, Tadaatsu Imaizumi, Tomomi Aizawa, Shojiro Watanabe, Koji Tsugawa, Shogo Kawaguchi, Kazuhiko Seya, Tomoh Matsumiya, Hiroshi Tanaka
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Series:	Renal Failure
Subjects:	chloroquine glomerular endothelial cells hydroxychloroquine lupus nephritis toll-like receptor 3
Online Access:	http://dx.doi.org/10.1080/0886022X.2021.1908901

Similar Items

Cytosolic Sensors of Viral RNA Are Involved in the Production of Interleukin-6 via Toll-Like Receptor 3 Signaling in Human Glomerular Endothelial Cells
by: Qiang Liu, et al.
Published: (2019-02-01)

Interleukin-6 via Toll-Like Receptor 3 Signaling Attenuates the Expression of Proinflammatory Chemokines in Human Podocytes
by: Hidenori Umetsu, et al.
Published: (2021-04-01)

IFIT Proteins Are Involved in CXCL10 Expression in Human Glomerular Endothelial Cells Treated with a Toll-Like Receptor 3 Agonist
by: Tadaatsu Imaizumi, et al.
Published: (2020-12-01)

Expression of interferon-stimulated gene 20 (ISG20), an antiviral effector protein, in glomerular endothelial cells: possible involvement of ISG20 in lupus nephritis
by: Takao Karasawa, et al.
Published: (2023-12-01)

Cylindromatosis (CYLD), a Deubiquitinase, Attenuates Inflammatory Signaling Pathways by Activating Toll-Like Receptor 3 in Human Mesangial Cells
by: Tadaatsu Imaizumi, et al.
Published: (2017-11-01)

Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions
by: Mayra Souza Botelho, et al.
Published: (2021-11-01)

Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral Centre
by: Tomas Walhelm, et al.
Published: (2024-03-01)

Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19
by: Tzu-Chuan Ho, et al.
Published: (2021-02-01)

Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine
by: David M. Stevens, et al.
Published: (2020-12-01)

Chloroquine-Based Mitochondrial ATP Inhibitors
by: Zhiguo Wang, et al.
Published: (2023-01-01)

Use of chloroquine and hydroxychloroquine in COVID-19 patients: A dilemma
by: Archana Bhatia, et al.
Published: (2022-01-01)

A Subject Review on a Some Analytical Methods for the Determination of Chloroquine and Hydroxychloroquine Drugs
by: Ali Khalil Mahmood, et al.
Published: (2022-01-01)

Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
by: Praveen Balabaskaran Nina, et al.
Published: (2020-01-01)

Clinical Efficacy of Hydroxychloroquine or Chloroquine in Patients with COVID-19: An Umbrella Review
by: Kavous Shahsavarinia, et al.
Published: (2021-12-01)

Crescentic glomerular nephritis associated with rheumatoid arthritis: a case report
by: K. Balendran, et al.
Published: (2017-07-01)

Measuring the energy for the molecular graphs of antiviral agents: Hydroxychloroquine, Chloroquine and Remdesivir
by: Muhammad Haroon Aftab, et al.
Published: (2024-01-01)

Early Alterations of QTc in Patients with COVID-19 Treated with Hydroxychloroquine or Chloroquine in Libreville, Gabon
by: Elsa Ayo Bivigou, et al.
Published: (2022-06-01)

A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer
by: Amal Kamal Abdel-Aziz, et al.
Published: (2022-10-01)

Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer
by: Britney Niemann, et al.
Published: (2022-11-01)

New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine
by: Davide Gentile, et al.
Published: (2020-08-01)

Synthesis and structure of new modified derivatives based on the quinine molecule and their biological activity
by: Mukusheva Gulim, et al.
Published: (2023-03-01)

Insights into the mechanisms of action of chloroquine and hydroxychloroquine and its use in COVID-19 for chemoprophylaxis
by: Monalisa Sahu, et al.
Published: (2021-01-01)

Knowledge-based assessment of polymorphism in crystal structures involving chloroquine and hydroxychloroquine
by: Samuel Tetteh
Published: (2022-01-01)

Retinal toxicity induced by antimalarial drugs: literature review and case report
by: Manuel Garza-Leon, et al.
Published: (2016-06-01)

Caution of retinal toxicity using chloroquine and hydroxychloroquine in the treatment of COVID-19
by: Li-Yuan Wang, et al.
Published: (2020-07-01)

Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
by: Jarir At Thobari
Published: (2021-08-01)

An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy
by: Stefano Celotto, et al.
Published: (2021-02-01)

Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine
by: Babayeva M, et al.
Published: (2020-10-01)

Chloroquine Urea Derivatives: Synthesis and Antitumor Activity in Vitro
by: Pavić Kristina, et al.
Published: (2018-12-01)

Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety
by: Michael Takla, et al.
Published: (2020-12-01)

Targeting Autophagy in Breast Cancer
by: Stefania Cocco, et al.
Published: (2020-10-01)

Ultrasonic Synthesis and Preliminary Evaluation of Anticoronaviral Activity of 6,7-Dimethoxy-4-(4-(4-methoxyphenyl)piperazin-1-yl)-1-methylquinolin-1-ium Iodide
by: Aleksey A. Vasilev, et al.
Published: (2022-07-01)

Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review
by: Samiha Mohsen, et al.
Published: (2022-03-01)

Combination of Autophagy Selective Therapeutics With Doxil: An Assessment of Pathological Toxicity
by: Kristi L. Helke, et al.
Published: (2022-06-01)

Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19
by: S. Saqrane, et al.
Published: (2020-05-01)

Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation
by: Belayneh A
Published: (2020-09-01)

Pharmacological management of COVID-19
by: Veena Raghunathan, et al.
Published: (2020-01-01)

Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19
by: Hongwei Peng, et al.
Published: (2020-10-01)

Hydroxychloroquine and chloroquine in prophylaxis and treatment of COVID-19: What is known?
by: Pathiyil Ravi Shankar, et al.
Published: (2021-01-01)

QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia
by: Rizki A. Gumilang, et al.
Published: (2021-10-01)